IL1B and psoriasis: The data available in the literature reporting on the elevated IL-1β levels in psoriasis lesions, which is consistent with our findings, as well as significantly decreased levels of this cytokine in response to anti-inflammatory therapy (27, 28), support the notion that psoriasis patients may benefit from the use of drugs that downregulate IL-1β production.